Generic DESERPIDINE; METHYCLOTHIAZIDE INN entry, drug patent expiry and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	ENDURONYL FORTE	deserpidine; methyclothiazide	TABLET;ORAL	012775-002	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	METHYCLOTHIAZIDE AND DESERPIDINE	deserpidine; methyclothiazide	TABLET;ORAL	088452-001	Aug 10, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	METHYCLOTHIAZIDE AND DESERPIDINE	deserpidine; methyclothiazide	TABLET;ORAL	088486-001	Aug 10, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 5, 2026

Deserpidine/methyclothiazide is a legacy antihypertensive combination with no meaningful branded-market growth, limited commercial visibility, and an effectively expired intellectual-property position. The product combines deserpidine, a rauwolfia alkaloid that reduces sympathetic nervous-system activity, with methyclothiazide, a thiazide diuretic. Its clinical role has been displaced by newer thiazide-based regimens, renin-angiotensin system inhibitors, calcium-channel blockers, and fixed-dose combinations with stronger guideline support.

No reliable public source reports current product-level revenue for deserpidine/methyclothiazide. The commercial trajectory is best characterized as historical decline followed by residual, low-volume availability rather than an active growth market.

What is deserpidine/methyclothiazide and how does it work?

Deserpidine/methyclothiazide is an oral antihypertensive combination.

Component	Pharmacologic role	Commercial implication
Deserpidine	Depletes catecholamines from sympathetic nerve endings and lowers vascular tone	Older mechanism with substantial tolerability and safety limitations
Methyclothiazide	Inhibits sodium reabsorption in the distal convoluted tubule	Established diuretic class, but less commonly selected than hydrochlorothiazide, chlorthalidone, or indapamide
Combination	Reduces blood pressure through complementary mechanisms	Fixed-dose convenience did not offset clinical displacement

Deserpidine is associated with adverse effects characteristic of older sympatholytic agents, including nasal congestion, sedation, gastrointestinal effects, orthostatic symptoms, and depressive reactions. Methyclothiazide can cause hypokalemia, hyponatremia, hyperuricemia, glucose intolerance, and other thiazide-related effects. The combination therefore competes against better-established and more flexible antihypertensive options.

When did deserpidine/methyclothiazide enter the market?

The combination belongs to the first generation of fixed-dose antihypertensive products introduced during the mid-20th-century expansion of pharmacologic hypertension treatment. It has been marketed under the brand name Diupres and through generic or legacy-label channels.

The product predates the modern Hatch-Waxman patent framework and the current FDA exclusivity system. Its original commercial protection was based primarily on historical formulation and regulatory positioning rather than a modern patent estate covering a novel molecular entity.

Key historical timeline

Period	Market event
1950s-1960s	Reserpine-related and other rauwolfia-derived antihypertensive products enter clinical use
1960s	Deserpidine/methyclothiazide combination products are marketed for hypertension
1970s-1980s	Thiazide monotherapy and newer antihypertensive classes expand
1990s	ACE inhibitors, calcium-channel blockers, beta blockers, and angiotensin-receptor blockers reduce use of rauwolfia combinations
2000s	Product becomes a legacy antihypertensive with limited commercial differentiation
Current market	No credible evidence of meaningful branded growth or active innovation investment

The FDA’s historical approval records and labeling databases identify the ingredients and product labeling, but they do not provide a current, standalone revenue series for the combination. (U.S. Food and Drug Administration, n.d.-a; National Library of Medicine, n.d.)

What patents protect deserpidine/methyclothiazide?

No active composition-of-matter patent is expected to protect deserpidine, methyclothiazide, or their combination. Both active ingredients were developed and marketed decades ago, placing any original patent protection far beyond the normal 20-year patent term established under modern U.S. patent law.

Patent-estate assessment

IP category	Current assessment
Deserpidine composition patent	Expired or otherwise commercially irrelevant
Methyclothiazide composition patent	Expired or otherwise commercially irrelevant
Fixed-dose combination patent	Any original protection is expired
New formulation patents	No material active estate publicly associated with the legacy combination
Method-of-use patents	No significant current exclusivity identified
Manufacturing patents	No known barrier that would prevent conventional generic manufacture
Regulatory exclusivity	No current meaningful exclusivity expected
Trademark	Historical brand rights may exist but have limited economic value

The commercial freedom-to-operate risk is therefore low for conventional tablets containing the two established active ingredients. Potential issues would relate to product-specific labeling, manufacturing controls, tablet design, or jurisdiction-specific registrations rather than core pharmaceutical patents.

What is the Orange Book status of deserpidine/methyclothiazide?

The product does not have the commercial profile of an actively protected reference product in the FDA Orange Book. The Orange Book is designed primarily to identify approved drug products, therapeutic-equivalence evaluations, patents submitted for listed products, and regulatory exclusivities. A legacy product may have historical approval records without having current patent or exclusivity protection.

A practical Orange Book assessment is:

No active exclusivity period drives the U.S. market.
No meaningful patent cliff remains.
Any generic competition is not waiting for a near-term patent expiration.
The principal barrier is commercial demand, not intellectual property.

FDA Orange Book listings and Drugs@FDA records should be distinguished from the existence of historical labeling. A product can have archived or legacy regulatory documentation without supporting a viable branded market. (U.S. Food and Drug Administration, n.d.-a; U.S. Food and Drug Administration, n.d.-b)

When does deserpidine/methyclothiazide lose exclusivity?

The product’s core exclusivity expired many years ago. There is no commercially relevant future loss-of-exclusivity date comparable to products protected by modern composition patents, pediatric exclusivity, orphan exclusivity, or data exclusivity.

Exclusivity profile

Protection type	Status
New chemical entity exclusivity	Expired
Composition-of-matter patent	Expired
Combination patent	Expired or immaterial
Pediatric exclusivity	Not commercially relevant
Orphan exclusivity	Not applicable
Biosimilar exclusivity	Not applicable
Current FDA marketing exclusivity	None of material commercial significance

Because deserpidine/methyclothiazide is a small-molecule combination, biosimilar provisions do not apply. Generic approval, where available, would proceed through an abbreviated new drug application or another applicable small-molecule pathway rather than the biosimilar pathway.

Are there Paragraph IV challenges for deserpidine/methyclothiazide?

A commercially significant Paragraph IV campaign is unlikely. Paragraph IV litigation is generally used when a generic applicant challenges an unexpired patent listed for an approved reference drug. Deserpidine/methyclothiazide has no apparent active patent barrier that would justify a major current challenge.

No high-value, current Paragraph IV litigation involving this combination is a recognized driver of market access, valuation, or launch timing. Any historic generic filings would have had limited strategic value because the underlying product has low demand and limited pricing power.

What formulation patents protect the product?

No material current formulation patent estate is associated with the conventional deserpidine/methyclothiazide tablet.

The product’s formulation is technically straightforward:

Oral tablet dosage form
Fixed quantities of two established active ingredients
Conventional excipients and compression processes
No biologic manufacturing platform
No depot injection, transdermal system, inhalation device, or complex delivery technology

A competitor could potentially design around a specific inactive-ingredient profile, tablet geometry, or manufacturing process without affecting access to the active ingredients. Those technical variables have little commercial importance unless a manufacturer is pursuing a narrow hospital, government, or specialty-distribution contract.

How strong is the patent estate for deserpidine/methyclothiazide?

The patent estate is weak from a business-development and litigation perspective.

Patent-strength factor	Assessment
Remaining patent life	None of material value
Claim breadth	Legacy combination claims, if any, are no longer commercially blocking
Design-around difficulty	Low
Generic substitution risk	High where supply is available
Litigation leverage	Low
Licensing value	Minimal
Manufacturing defensibility	Low to moderate, based on quality and supply execution rather than IP

The product may still have regulatory or operational barriers. A manufacturer must maintain compliant sourcing, validated production, stability data, pharmacovigilance, and reliable distribution. Those are execution requirements, not durable exclusivity mechanisms.

What is the competitive landscape for deserpidine/methyclothiazide?

The combination competes against therapies with stronger clinical adoption and broader formulary presence.

Main competitive classes

Competitive class	Examples	Competitive advantage
Thiazide and thiazide-like diuretics	Hydrochlorothiazide, chlorthalidone, indapamide	Familiarity and guideline integration
ACE inhibitors	Lisinopril, enalapril	Strong evidence base and broad use
ARBs	Losartan, valsartan, irbesartan	Tolerability and fixed-dose combinations
Calcium-channel blockers	Amlodipine, nifedipine	Effective once-daily therapy
Beta blockers	Metoprolol, atenolol	Selected cardiovascular indications
Modern fixed-dose combinations	ARB/thiazide, ACE inhibitor/CCB, ARB/CCB	Better prescribing flexibility and commercial support

Guidelines from the American College of Cardiology and American Heart Association generally prioritize thiazide-type diuretics, ACE inhibitors, ARBs, and calcium-channel blockers, depending on patient characteristics. Deserpidine is not a routine first-line component of contemporary hypertension treatment. (Whelton et al., 2018)

The combination’s main disadvantage is not price. It is clinical obsolescence relative to drugs with better evidence, more predictable use, and stronger physician familiarity.

What is the FDA regulatory status?

The product is a conventional small-molecule antihypertensive, not a biologic, biosimilar, controlled substance, or advanced therapy. FDA regulatory value is limited by the product’s age and narrow commercial relevance.

Relevant regulatory characteristics include:

Prescription antihypertensive classification
Oral fixed-dose tablet
No biosimilar pathway
No current innovation exclusivity
Legacy labeling and safety information
Limited strategic value from a new drug application unless a sponsor seeks a reformulation or relaunch

A relaunch would require more than acquiring a historical label. The sponsor would need to establish current manufacturing compliance, product availability, labeling strategy, pharmacovigilance, and a commercially credible reason for physicians and payers to use the product.

Which companies are challenging or commercializing the product?

No major current competitor is publicly associated with an active branded investment campaign for deserpidine/methyclothiazide. The market is more likely to consist of legacy-label holders, contract manufacturers, small generic companies, and distributors than large pharmaceutical innovators.

The commercial landscape is fragmented because:

The active ingredients are old and inexpensive.
Demand is limited.
Switching costs are low.
Prescribers have many alternatives.
There is no meaningful patent-based market window.
Marketing investment would be difficult to recover.

No major licensing transaction, acquisition premium, or strategic partnership is publicly recognized as being driven by this specific combination. Any licensing value would likely depend on a broader portfolio transaction involving legacy antihypertensive products rather than the combination alone.

What is the financial trajectory of deserpidine/methyclothiazide?

The financial trajectory is structurally negative or flat at a very low base.

Revenue drivers

Driver	Effect on financial outlook
Unit demand	Declining as prescribing shifts to modern agents
Average selling price	Low because of generic competition and limited differentiation
Gross margin	Potentially acceptable for a low-cost legacy product, but vulnerable to small-volume manufacturing
Marketing expense	Usually limited because market expansion is unlikely
Supply economics	Can be unfavorable if batch sizes are small
Pricing power	Weak
Reimbursement leverage	Limited
Licensing value	Low
Litigation value	Negligible

A small supplier may retain the product because it fills a portfolio gap, uses existing manufacturing capacity, or serves a residual patient population. That does not imply attractive growth. The asset can remain commercially available while generating little strategic value.

What generic launch risks exist?

Generic launch risk is low from a patent perspective but moderate from a supply and market-size perspective.

Generic entry scenario

Scenario	Likely outcome
New generic entrant	Rapid price pressure if demand is sufficient
Existing supplier exits	Temporary shortage risk because few manufacturers may remain
Brand relaunch	Low probability without a differentiated formulation or channel
Authorized generic	Limited strategic rationale
Reformulation	Commercially difficult unless linked to a new indication or delivery advantage
Manufacturing transfer	Manageable but potentially uneconomic at low volumes

The principal risk is not a sudden patent-enabled generic wave. It is gradual erosion, intermittent supply, and eventual withdrawal if production costs exceed contribution margin.

What geographic coverage does the product have?

Deserpidine/methyclothiazide has limited strategic relevance outside markets where legacy antihypertensive products remain registered and where low-cost treatment access supports continued use.

Geographic commercialization is constrained by:

Country-specific registration status
Local availability of active pharmaceutical ingredients
Pharmacopoeial and quality requirements
National treatment guidelines
Reimbursement policies
Small patient populations
Lack of multinational promotional support

The United States offers little apparent growth potential. International residual markets may exist, but they are unlikely to create a material global revenue opportunity without evidence of active registrations, supply contracts, or local demand.

Key Takeaways

Deserpidine/methyclothiazide is a legacy fixed-dose antihypertensive combination with minimal current commercial momentum.
Its active ingredients and combination technology are long past the period of meaningful patent exclusivity.
No material current Orange Book patent or regulatory-exclusivity barrier drives market access.
Paragraph IV litigation and biosimilar risk are not meaningful factors.
The formulation is a conventional oral tablet with low technical and IP defensibility.
Modern antihypertensive classes have displaced deserpidine in routine prescribing.
Product-level revenue is not publicly disclosed, but the market profile indicates low and declining revenue.
Residual value depends on supply continuity, portfolio economics, and niche distribution rather than innovation or patent protection.
A generic entrant could access the market without facing a meaningful core patent barrier, although limited demand may reduce launch incentives.

FAQs

Is deserpidine/methyclothiazide still used for high blood pressure?

It may remain available in limited markets or through legacy supply channels, but it is not a routine first-line choice in contemporary hypertension management.

Is Diupres still a patented drug?

No commercially meaningful patent protection is expected to remain for the original deserpidine/methyclothiazide combination.

Can a generic manufacturer launch deserpidine/methyclothiazide?

A manufacturer could pursue the applicable FDA small-molecule approval pathway, subject to current regulatory, manufacturing, and labeling requirements. Patent-based launch restrictions do not appear to be the principal barrier.

Does deserpidine/methyclothiazide have biosimilar competition?

No. Biosimilars apply to biologic products. Deserpidine/methyclothiazide is a conventional small-molecule tablet.

Why did deserpidine/methyclothiazide lose market share?

Physicians shifted toward antihypertensive agents with stronger clinical evidence, better tolerability, broader guideline support, and more flexible fixed-dose combinations.

References

National Library of Medicine. (n.d.). DailyMed: Deserpidine and methyclothiazide tablet labeling. U.S. National Library of Medicine.
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. Center for Drug Evaluation and Research.
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, 45th edition. Center for Drug Evaluation and Research.
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., MacLaughlin, E. J., Muntner, P., Ovbiagele, B., Smith, S. C., Spencer, C. C., Stafford, R. S., Taler, S. J., Thomas, R. J., Williams, K. A., Williamson, J. D., & Wright, J. T. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115. https://doi.org/10.1161/HYP.0000000000000065

US Patents:	0
Tradenames:	3
Applicants:	2
NDAs:	3
DailyMed Link:	DESERPIDINE; METHYCLOTHIAZIDE at DailyMed

DESERPIDINE; METHYCLOTHIAZIDE - Generic Drug Details

What are the generic drug sources for deserpidine; methyclothiazide and what is the scope of freedom to operate?

Summary for DESERPIDINE; METHYCLOTHIAZIDE

Anatomical Therapeutic Chemical (ATC) Classes for DESERPIDINE; METHYCLOTHIAZIDE

US Patents and Regulatory Information for DESERPIDINE; METHYCLOTHIAZIDE

Deserpidine and Methyclothiazide Market Dynamics, Patent Status, and Financial Trajectory